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Abstract
Background. Secondary prevention is efficient in reducing morbidity and mortality after a myo-
cardial infarction (MI). However, both short-term and long-term mortality after MI remains rela-
tivity high in type 2 diabetes patients.
Objective. To evaluate repeat prescriptions of secondary prevention medication (anti-throm-
botic agent, beta-blocker and statin) in type 2 diabetes patients with a previous MI.
Methods. Data of 1009 type 2 diabetes patients with a previous MI were extracted from the 
Julius General Practitioners’ Network database. The proportion of patients with recent repeat 
prescriptions of guideline-based medication was determined. Furthermore, repeat prescriptions 
was determined 6 months, 1 year, 2 years and 5 years after MI. Generalized linear models were 
used to examine changes over time. Multivariate logistic regression analysis was used to ana-
lyse the association between patient characteristics and prescription.
Results. Only 46% of all type 2 diabetes patients with a previous MI had a recent repeat pre-
scription for all three medicines. An increase in prescription over time was found for statins 
(P = 0.001). Older aged people [odds ratio (OR): 0.99, 95% confidence interval (CI): 0.98–1.00] 
were less likely to receive the combination of all three.
Conclusion. A substantial proportion of type 2 diabetes patients with a previous MI did not 
receive guideline-based secondary prevention. Prescription rates were quite stable over time. 
This study confirms the need for a different approach to achieve an improvement of secondary 
prevention in type 2 diabetes patient with a previous MI. GPs can play an important role in this 
respect by being extra alert that prescription occurs according to the guidelines.
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Introduction
Patients with type 2 diabetes mellitus are at higher risk of cardio-
vascular events, compared with patients without diabetes. Over 
the last decades, mortality rates after myocardial infarction (MI) 
have decreased in the Netherlands due to improved treatment in 
the acute phase and more aggressive secondary prevention (1). 
Nevertheless, mortality is relatively high among type 2 diabe-
tes patients compared with patients without diabetes, especially 
after recurrent events (1). Evidence-based secondary prevention 
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medication is efficient in reducing mortality and morbidity after 
MI (2). Guidelines on secondary prevention therapy include a 
lifelong repeat prescription of at least a combination of an anti-
thrombotic agent, a beta-blocker and a statin to all patients (3). 
In the Netherlands, the cardiologist is responsible for the ini-
tial prescription of secondary prevention therapy. After hospital 
discharge, the GP manages lifelong repeat prescriptions. It has 
been found that although the combination of these medicines 
is initially prescribed in 70% of the patients at discharge, after 
1 month only 48% continues to use all three (4).
Previous research in Dutch primary care showed that the 
quality of diabetes care has improved over the past years, with 
improvements in adherence to management guidelines in terms 
of recommended process measures and good intermediate car-
diometabolic outcomes (including HbA1c, blood pressure, cho-
lesterol levels) in type 2 diabetes (5). However, undertreatment 
for blood pressure and glucose remained prevalent in 61% and 
53% of the patients (6). In other countries, secondary preven-
tion therapy was unsatisfactory in cardiovascular patients, 
especially patients with type 2 diabetes did not reach treatment 
targets (7,8). This insufficient secondary prevention has been 
associated with several patient characteristics such as older age, 
female gender, less comorbidity and a low social-economic sta-
tus (9,10). Against that background, and taking into account 
that mortality remains relatively high in type 2 diabetes after 
an MI, the aim of this study was to evaluate the level of ongo-
ing secondary prevention in type 2 diabetes patients with previ-
ous MI in Dutch primary care. It should be noted that in the 
Netherlands anti-thrombotic agents, beta-blockers and statins 
are in principle all fully reimbursed for all patients. We aimed 
to examine whether type 2 diabetes patients with a previous MI 
have ongoing repeat prescriptions of guideline-based preventive 
medication and to assess the association between patient char-
acteristics and the above-mentioned medicines. Furthermore, we 
assessed the changes in prescription rates over time after the MI.
Methods
Study population
Data were obtained from the Julius General Practitioners’ 
Network (JGPN) database, which contains routine health care 
data anonymously extracted from electronic primary care set-
tings in the area of Utrecht (11). The database includes data on 
medication prescribed by both primary care and secondary care 
physicians. We used data from 56 general practices, covering a 
population of 11 267 type 2 diabetes patients [coded according 
to the International Classification of Primary Care (ICPC) as 
T90.02]. Inclusion criteria were (i) a diagnosis of type 2 diabetes 
and (ii) a previous MI. Exclusion criteria were (i) a diagnosis of 
type 2 diabetes before the age of 35 years; (ii) no or incorrect 
data on date of birth, type 2 diabetes diagnosis and/or occur-
rence of MI; and (iii) no longer registered at one of the general 
practice included in the JGPN (Fig. 1).
Measures
Data were extracted between March 2012 and July 2012. From 
all included patients, data were retrieved with regard to patient 
characteristics, prescribed medicines, date of diagnosis of type 2 
diabetes and date of occurrence of MI (ICPC K75.00 or K76.00). 
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Patient characteristics included age, gender and socioeconomic 
status (SES). Low SES was defined as whether the patient lives 
in a areas with postal codes belonging to disadvantaged areas 
(12). Prescription of guideline-based medication was defined as 
a prescription of an anti-thrombotic agent (ATC B01A), a statin 
(ATC C10AA) and a beta-blocker (ATC C07A). Recent (i.e. at 
date of data extraction) repeat prescription was defined as being 
present if any beta-blocker, any statin and any platelet aggrega-
tion inhibitor or oral anticoagulant had been prescribed within 
6 months before data extraction.
Statistical analysis
Baseline characteristics are presented as mean values with stand-
ard deviations or numbers with percentages. The proportion 
of patients with recent repeat prescriptions of the above-men-
tioned classes of drugs was calculated. In addition, prescription 
rates were determined at different time points after MI (after 
6 months, 1 year, 2 years and 5 years). Generalized linear models 
for repeated measures were used to examine changes over time. 
When appropriate, a Bonferroni test for multiple comparisons 
was used for post-hoc analysis.
To evaluate the association between age, gender, SES and dura-
tion of type 2 diabetes on the one hand and repeat prescription on 
the other, multivariate logistic regression analysis was performed. 
To determine if the prescription rate was influenced by whether 
the MI occurred before or after type 2 diabetes diagnosis, chi-
square tests were used to compare recent prescription rates of the 
three medicines and the combination in the group who first had 
type 2 diabetes with the group who first had the MI. All analyses 
were performed using SPSS version 20.0 (IBM SPSS statistics).
Results
Baseline characteristics
The study population consisted of 1009 patients (mean age 
71.2 ± 10.8 years; 68% male) with type 2 diabetes and previous 
MI (Table 1). The median [inter quartile range (IQR)] duration 
since diagnosis of type 2 diabetes was 6.0 (3.0–9.0) years. The 
median (IQR) time since MI was 6.1 (3.1–12.5) years. A  low 
SES score was found in 15% of the patients (n = 154).
Secondary prevention
Of all patients with type 2 diabetes and previous MI, only 46% 
were recently (i.e. at date of data extraction) registered with pre-
scriptions of all three recommended medicines (Table  1). The 
proportion of patients with a repeat prescription for at least 
one of the three guideline-based medications was much higher, 
namely 87%. Of the three medications, beta-blockers were 
the least prescribed (60%) and anti-thrombotic agents were 
most often prescribed (78%; Table 1). Regarding time elapsed 
since MI, no differences were found for anti-thrombotic agent, 
beta-blocker and the combination for the three medications 
(Fig. 2). Change in prescription rates over time was found for 
statin prescription (P = 0.001). Post-hoc analyses revealed sig-
nificant increases between prescription rates at 6  months and 
1 year (61% versus 69%, P = 0.019), and between 6 months 
and 5 years (61% versus 71%, P = 0.002), with the lowest pre-
scription rates at 6 months after MI. In 45% of the patients, 
the occurrence of MI was before the date type 2 diabetes was 
diagnosed. In these patients, the MI was diagnosed on average 
8.6 ± 7.0 years before the diagnosis of type 2 diabetes. Whether 
the occurrence of MI was before or after the type 2 diabetes 
diagnosis had no impact on the prescription rates (anti-throm-
botic agent: chi-square = 0.092, P  = 0.762; beta-blocker: chi-
square = 0.306, P = 0.580; statin: chi-square = 1.497, P = 0.762; 
all three: chi-square = 0.125, P = 0.724).
Determinants of treatment
A 1-year increase in age decreases the odds of getting all medi-
cines prescribed by ~1.3% (OR: 0.99, 95% CI: 0.98–1.00; 
Table 2). Analysis of determinants for a repeat prescription of 
one of the three medicines showed that women were less likely 
than men to have a repeat prescription of an anti-thrombotic 
agent (OR: 0.73, 95% CI: 0.53–0.99). Older aged patients had 
less frequently a repeat prescription for a statin (OR: 0.98, 95% 
CI: 0.97–0.99; Table 2).
Conclusions
The results of this study show that a substantial proportion of 
type 2 diabetes patients who experienced an MI did not receive 
Table 1. Characteristics of type 2 diabetes patients with 
MI and proportion ongoing (i.e. between March 2012–July 
2012) prescription rates of secondary prevention medication
n = 1009
Age (mean, SD) 71.2 ± 10.8
Male gender (%, n) 67.6 (682)
Median (IQR) duration since type 2 diabetes  
diagnosis (years)
6.0 (3.0–9.0)
Median (IQR) duration since MI (years) 6.1 (3.1–12.5)
Low social-economic status (%, n) 15.3 (154)
Occurrence MI before diagnosis type  
2 diabetes (%, n)
45.1 (455)
Medication type (%, n)
 Anti-thrombotic agent 77.8 (785)
 Beta-blocker 60.2 (607)
 Statin 70.4 (710)
 All three 45.9 (338)
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optimal evidence-based secondary cardiovascular prevention. 
Only 46% of the patients was found to have ongoing repeat 
prescriptions for the combination of an anti-thrombotic agent, 
a beta-blocker and a statin. The lowest recent repeat prescrip-
tion rates were found in older patients. The prescription rates 
were quite stable over time, with only a significant increase in 
the proportion of patients with a repeat prescription of a statin.
The proportion of patients with prescriptions for guideline-
based medication in our study is within range of previously 
found proportions (for beta-blocker and statin). In a study in 
India among 2290 patients with heart disease (45% with type 2 
diabetes), 89% had a prescription for aspirin, 59% for a beta-
blocker and 67% for a statin (13). In Ireland, a study among 
1746 diabetic patients with ischemic heart disease reported that 
77% had a prescription for aspirin, 35% for a beta-blocker and 
37% for a statin (14). These studies did not report the proportion 
of patients with the combination of the three medicines. The low 
percentage of patients with repeat prescriptions of guideline-
based medication in our study might be the result of an omission 
of prescribing at different moments. First, it is possible that the 
hospital-based physician responsible for secondary prevention 
did not initially prescribe all three drugs. However, it was pre-
viously found that prescription rates at discharge were much 
higher (anti-thrombotic agent: 91%; beta-blocker: 86%; statin: 
80%) (15). In that study, the combination of all three medicines 
was prescribed in 70% of the patients, but after 1 month only 
48% continues to use all three. Moreover, which medication is 
prescribed by the GP depends strongly on the initially prescribed 
medication in the hospital (16). A second possibility might be 
that patients do not visit the GP for repeat prescriptions and 
decide by themselves to discontinue the medication. A previous 
study showed that in 61% of the patients who discontinue medi-
cines, this was self-determined (17). In that study, an important 
factor associated with self-discontinuation was having no phar-
macy coinsurances. Since Dutch diabetes patients get full reim-
bursement, the proportion of patients self-discontinuing in our 
study is likely to be <61%. A third option is that the GP might 
decide together with the patient not to prescribe some of the 
medicines, for example because of side effects or drug interac-
tions. As described above, it is known that prescriptions rates 
are much higher at discharge and discontinuing occurs mostly 
in the first month after discharge without involvement of the GP. 
Table 2. Independent determinants for prescription of anti-thrombotic agent, beta-blocker, statin or the combination of all three
Anti-thrombotic agent Beta-blocker Statin All three
Determinant OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age 0.99 (0.98–1.04) 0.99 (0.98–1.01) 0.98 (0.97–0.99)** 0.99 (0.98–1.00)**
Gender (female ref) 0.73 (0.53–0.99)** 0.83 (0.64–1.08) 0.90 (0.67–1.19) 0.79 (0.61–1.03)*
SES (low ref) 0.79 (0.50–1.23) 0.75 (0.52–1.08) 0.90 (0.61–1.01) 0.78 (0.55–1.10)
Duration type 2 diabetes 1.01 (0.98–1.04) 1.01 (0.98–1.01) 0.99 (0.97–1.01) 1.00 (0.98–1.02)
*P < 0.10; **P < 0.05.
Figure 2. Proportion of prescriptions for guideline-based medication—changes over time after the MI.
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This might be the result of patients experiencing difficulties 
in coping with pharmacotherapy, especially in the first period 
after discharge, which in turn might induce discontinuation and 
the absence of repeat prescriptions on the long term. In a focus 
group study, we indeed found that patients with the combina-
tion of type 2 diabetes and MI, experienced difficulties after dis-
charge from hospital on coping with the amount of medicines 
and the adverse effects of pharmacotherapy (18). In our study, 
the proportion of patients receiving the guideline-based medica-
tion was already low in the first year after discharge and no fur-
ther decrease was seen in the following years. Moreover, a small 
increase over the years is found with higher prescription rates 
5 years after MI, especially for a statin. This increase might be 
explained by the fact that type 2 diabetes patients visit their GP 
regularly to control the diabetes and cardiovascular risk factors 
in a time period in which statin prescription has become more 
‘common’ and target levels decreased.
The suitability of guidelines to the individual patient care can 
be questioned. On the one hand, an individualized treatment 
approach and shared decision-making between patient and GP 
regarding treatment is important and appreciated by patients 
(19). On the other hand, guidelines are developed to be appli-
cable to the majority of the patients. Since discontinuation of 
secondary medication is associated with a higher mortality (15), 
it can be thought that it is important to prescribe medication 
according to the evidence-based guidelines. Although GPs may 
have good reasons not to prescribe the combination of all three 
medicines (e.g. the possible adverse effects could be considered 
being disproportionate to the benefits in prolonging life expec-
tancy), it is unlikely that they have such a good reason in the 
majority (in our study >50%) of the patients. Future studies 
should investigate the reasons for not prescribing according to 
the guidelines to provide insight into whether guidelines regard-
ing secondary prevention are not suitable to most of the type 2 
diabetes patients, and therefore should be adjusted, or whether 
strategies are needed to increase the adherence to guidelines.
Our findings concerning the determinants of secondary pre-
vention are comparable to other studies (9,10). Differential 
treatment patterns for women compared with men have been 
described earlier. Previous research showed that in type 2 dia-
betes, than women, men were more likely to receive a prescrip-
tion for aspirin than women (9). A possible explanation could 
be that physicians believe that men have a higher risk of future 
cardiovascular events than women. However, female gender is 
associated with a more adverse cardiovascular profile compared 
with male gender in diabetes (20). In Ireland women with type 
2 diabetes did not achieve the same decline in cardiovascular 
events and mortality as men (21). Insufficient therapy could at 
least partially explain the slower decline in male compared with 
female. Older patients were also less likely to receive preventive 
medicines, both in our study and in previous reports (10). In 
these patients, the possible adverse effects could be considered 
being disproportionate to the benefits in prolonging life expec-
tancy. According to Dutch GPs, prescribing preventive drugs in 
older patients also depends on the patient’s wishes and should be 
based on shared decision-making between GPs and patients (22).
In our study, 46% of the patients actually were diagnosed 
with MI before they were diagnosed with type 2 diabetes. It 
can be thought that having the diagnosis diabetes before hav-
ing the MI can influence prescription. However, no differences 
were found between the proportion of repeat prescriptions of 
the group with a type 2 diabetes diagnosis before or after the 
occurrence of an MI.
It is important to note that we only focussed on the prescrip-
tion of medication. Medication adherence is at least as impor-
tant. Approximately, a third of all patients who have had an MI 
do not adhere to cardiovascular preventive treatment in the long 
term (23). Our study does not provide information about the 
adherence to the prescribed drugs. However, to decrease mor-
tality and recurrence rates, guideline-based medication should 
be at least prescribed (4). In the National Institute for Health 
and Care Excellence guidance, the importance of the role of 
primary care in secondary prevention is emphasized (24). GPs 
and nurses are largely responsible for prescription and monitor-
ing of ongoing drug therapy. This requires effective communi-
cation between secondary and primary care and management 
plans should be fine-tuned between involved physicians. Also, 
the American Diabetes Association recommends structured dis-
charge planning that should include (i) medication reconcilia-
tion; (ii) structured discharge communication; (iii) discharge 
summary transmitted to primary care physician; (iv) follow-up 
visits scheduled with both primary and secondary care provid-
ers (25).
Our study had some limitations. First, we had no data on 
comorbidity. Therefore, we were not able to investigate the pos-
sible role of for example signs and symptoms of heart failure 
peripheral arterial disease and hypertension next to the deter-
minants used in this study. Furthermore, the updated guide-
lines on secondary prevention suggest to prescribe also an 
angiotensin receptor blocker instead of an angiotensin convert-
ing enzyme (ACE)-inhibitor in patients who are intolerant for 
ACE-inhibitors (24). Since this was not in the guidelines when 
our data were extracted, prescription rates of ACE-inhibitors/
angiotensin-II-inhibitors are likely to be biased in our study, and 
therefore we did not take these prescription rates into account 
in this study. Including ACE-inhibitors/angiotensin-II-inhibitors 
in our analysis would results in an unrealistic low proportion of 
patients with prescriptions of the combination of all four guide-
line-based medicines, by all means lower than the 46% found 
for the combination of all three.
In conclusion, a substantial proportion of patients with type 
2 diabetes and previous MI did not receive repeat prescriptions 
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of guideline-based secondary prevention medication. This is 
worrisome, since patients who do not receive repeat prescrip-
tions of guideline-based medication are at increased risk of 
future cardiovascular events. Older age was associated with 
less prescription of preventive medicines. Given the high risk of 
future cardiovascular disease, this study confirms the need for a 
different approach to achieve an improvement of secondary pre-
vention in patients with type 2 diabetes and previous MI, espe-
cially in older patients. GPs can play an important role in this 
respect by being extra alert that secondary prevention therapy 
occurs according to the guidelines. This issue could possibly be 
incorporated in the annual diabetes check-up.
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